Obesity management after kidney transplant
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a weight loss medication (semaglutide) can help manage obesity in people who have had a kidney transplant or are at high risk. It aims to improve health outcomes and prevent further kidney decline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- Your BMI (body mass index) is 35 or higher
- You have a 10% or greater chance of needing dialysis within 2 years, or you are already on dialysis
- You do not have any condition that prevents the use of GLP-1 receptor agonists (like pancreatitis, medullary thyroid cancer, or an allergy to the drug)
- You do not have type 1 diabetes
- You have a way to get semaglutide through your drug coverage
- You are not pregnant, breastfeeding, or planning to become pregnant
- You are not currently in another study testing GLP-1 receptor agonists
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a patient-centered program with virtual support to help people with obesity and advanced kidney disease lose weight and improve their chances of getting a kidney transplant. It uses a type of medication called a GLP-1 receptor agonist, which can help with weight loss.
This study tests whether weight loss from a medication can improve how you feel, move, and how well your heart works. It's for people who have both obesity and heart failure with reduced pumping strength.
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
This study tests a medication called semaglutide (a once-weekly injection) to help people with obesity lose weight. It is for adults who have already tried lifestyle changes without success.
This study tests whether a low dose of semaglutide (a once-weekly injection) can help obese adults without diabetes lose weight. Semaglutide works by reducing appetite and helping your body use food differently.
This Phase 2 study tests a program to help people with chronic kidney disease (CKD) sit less and move more, plus a medication (semaglutide) for those who qualify. It may help improve health and day-to-day activity while monitoring safety closely.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.